Auckland, New Zealand and New York, NY (October 11, 2002) -- In a study published today in the journal "Science," scientists from the University of Auckland and Weill Cornell Medical College report on the effectiveness of a new gene therapy approach to Parkinson's disease, and the potential for this therapy to affect the overall progression of the disease itself. Based on this study and other data, the U.S. Food and Drug Administration (FDA) has given its approval to begin testing this therapy in a small Phase I clinical trial. This will be the first time in the world that gene therapy will be used in patients with Parkinson's disease.The "Science" publication is authored by lead investigator, Dr. Matthew J. During, Professor of Molecular Medicine at the University of Auckland, first author Dr. Jia Luo, and co-investigator Dr. Michael G. Kaplitt, Director of Stereotactic and Functional Neurosurgery and Assistant Professor of Neurological Surgery at Weill Cornell Medical College. Dr. During and Dr. Kaplitt are also co-principal investigators on the upcoming clinical trial of this therapy.
NEW YORK (December 29, 2004) -- In any bioterror attack, vaccines that provide a rapid, effective defense against the pathogen will be key to saving lives.However, in the case of anthrax, vaccines available today can take weeks or even months to gain full effect.
Over 2,600 faculty, staff, retirees and their families attended the Nov. 1 Employee Celebration Day, where more than 150 people volunteered on the day or in planning. (Nov. 7, 2008)
Avian pathologist Stephen B. Hitchner, who taught and researched at Cornell's College of Veterinary Medicine 1966-81, has died at age 94. (Jan. 11, 2011)
Endowed employees will be able to cover their children ages 19-26 on Cornell health/dental plans, and all employees will be able to cover them on Select Benefits medical reimbursement plans. (July 13, 2010)
New York, NY (June 7, 2002) In a new study just published in the journal Circulation Research, scientists at Weill Cornell Medical College demonstrate that therapy with bone-marrow-derived precursor cells can restore aging cardiac blood vessel-forming capacity, thus possibly preventing some of the morbidity and mortality associated with ischemic heart disease in older individuals. The study points to a promising and novel approach to preventing and treating heart disease in the aging.The lead author, Dr. Jay Edelberg, Assistant Professor of Medicine in the Division of Cardiology at Weill Cornell and Assistant Attending Physician at NewYork-Presbyterian Hospital's Weill Cornell Medical Center, says the study, in an animal model, builds on previous research in his lab that examined changes in the endothelial cells that line the blood vessels of older hearts. That study found that molecular alterations in those aged cells lead to a dysregulation of a molecular pathway by which platelet-derived growth factor (PDGF) normally contributes to angiogenesis, or new blood vessel formation. In the new study, he and his colleagues show the possibility of restoring this pathway by bone marrow transplantation.
Editor's picks for events the week of Dec. 12 include midyear graduation, Neanderthal sculpture, Middle Eastern folk tales and a concerto competition. (Dec. 11, 2008)
Physicians may someday monitor a patient's blood flow, blood pressure and temperature with tiny, implantable devices -- some small enough to be injected into a person's vascular system -- thanks to research by a Cornell…
The Southern Tier Law Enforcement Academy at Corning Community College graduated its 17th session of police recruits from the New York State Basic Course for Police Officers, March 10, and Cornell University Police recruits who attended earned several awards.
A remarkable facility producing some of the world's most intense X-ray beams for research, education and training will be dedicated at Cornell Univeristy Tuesday, June 15. Known as G-line, it is the world's only such center on the central campus of a major research university. Built by Cornell and housing equipment purchased through National Science Foundation (NSF) grants, G-Line is dedicated to Cornell research and education in technology, biology and materials science. Annual operating costs will be paid by 10 of the university's research groups. (June 10, 2004)